Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2021 Oct 18;9(10):e002919. doi: 10.1136/jitc-2021-002919

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© Author(s) (or their employer(s)) 2021. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ.

This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, appropriate credit is given, any changes made indicated, and the use is non-commercial. See http://creativecommons.org/licenses/by-nc/4.0/.

PMC Copyright notice

Changes in immune cell subsets and specific immune markers in a patient with prolonged response (#11). A) Line graphs showing immune cell phenotypes by Nanostring at baseline (Pre), and after treatment with tremelimumab and durvalumab (Post) in patient #11. B) Line graphs showing expression of immune markers by gene expression at baseline (Pre), and after treatment with tremelimumab and durvalumab (Post) for patient #11. Red line denotes patient #11; black line denotes median values of each cell type/immune marker for remaining 13 patients.